Analyst maintains confidence in BSX despite near-term pressures, citing achievable Q2 2026 guidance and 65% upside potential.
TD Cowen analyst Josh Jennings reiterated a Buy rating on Boston Scientific (BSX) with a $61 price target, citing resilience despite a 52% year-to-date decline. The firm expects over 65% upside from current levels, driven by achievable fiscal Q2 2026 revenue and EPS guidance.
Recent earnings expectations have softened, improving the likelihood of meeting the lower end of guidance. While US Watchman sales and select franchises underperformed, management projects organic growth within targeted ranges for Q2 and full-year 2026.
Boston Scientific specializes in medical devices for interventional specialties, operating in MedSurg and Cardiovascular segments. The stock’s decline contrasts with analyst optimism about long-term recovery potential.